One of the aims of modern medicine is perfecting the way we tests treatments and drugs, so that the lengthy guess-work and clinical trials can be shortened or even cut out of the equation. While this would not only ensure the speedier delivery of drugs to market, it would also eliminate the need for animal testing, something which has become increasingly common and controversial in recent years.
Over the last century, animal testing has expanded from biomedical research to included things like drug, chemical, and cosmetic testing. One 2008 study conducted by The Guardian estimated that 115 million animals are used a year for scientific research alone. It is therefore no surprise that opposition is growing, and that researchers, regulators and even military developers are looking for more accurate, efficient, and cruelty-free alternatives.
Enter the National Insitute of Health in Besthesda, Maryland; where researchers have teamed up with the FDA and even DARPA to produce a major alternative. Known as the “Human Body-on-a Chip”, this device is similar to other “Organs-on-a-chip” in that it is basically a small, flexible pieces of plastic with hollow micro-fluidic channels lined with human cells that can mimic human systems far more effectively than simple petri dish cell cultures.
Dan Tagle, the associate director of the NIH’s National Center for Advancing Translational Sciences, explained the benefits of this technology as follows:
If our goal is to create better drugs, in a way that is much more efficient, time and cost-wise, I think it’s almost inevitable that we will have to either minimize or do away with animal testing.
What’s more, chips like this one could do away with animal testing entirely, which is not only good news for animals and activists, but drug companies themselves. As it stands, pharmaceutical companies have hit a wall in developing new drugs, with roughly 90% failing in human clinical trials based on safety and effectiveness. One reason for this high rate of failure is that drugs that first seem promising in rodents often don’t have the same response in people.
In fact, so-called “animal models” are only typically 30% to 60% predictive of human responses, and there are potentially life-saving drug therapies that never make it to human clinical trials because they’re toxic to mice. In these cases, there’s no way to measure the lost opportunity when animals predict the wrong response. And all told, it takes an average of 14 years and often billions of dollars to actually deliver a new drug to the market.
According to Geraldine Hamilton, a senior staff scientist at Harvard University’s Wyss Institute for Biologically Inspired Engineering, it all began five years ago with the “lung-on-a-chip”:
We’ve also got the lung, gut, liver and kidney. We’re working on skin. The goal is really to do the whole human body, and then we can fluidically link multiple chips to capture interactions between different organs and eventually recreate a body on a chip.
This has led to further developments in the technology, and Hamilton is now launching a new startup company to bring it to the commercial market. Emulate, the new startup that will license Wyss’s technology, isn’t looking to literally create a human body but rather to represent its “essential functions” and develop a platform that’s easy for all scientists and doctors to use, says Hamilton, who will become Emulate’s president and chief scientific officer.
Borrowing microfabrication techniques from the semiconductor industry, each organ-on-a-chip is built with small features – such as channels, vessels, and flexible membranes – designed to recreate the flow and forces that cells experience inside a human body. All that’s needed are different chips with different culture of human cells; then researchers can performed tests to see how drugs work in one region of the body before being metabolized by the liver.
This might one day help the military to test treatments for biological or chemical weapons, a process that is unethical (and illegal) with humans, and cruel and often inaccurate with animals. Hospitals may also be able to use a patient’s own stem cells to develop and test “personalized” treatments for their disease, and drug companies could more quickly screen promising new drugs to see if they are effective and what (if any) side effects they have on the body’s organs.
It’s a process that promises speedier tests, quicker delivery, a more cost-effective medical system, and the elimination of cruel and often inaccurate animal testing. Can you say win-win-win?
Human life expectancy has been gradually getting longer and longer over the past century, keeping pace with advances made in health and medical technologies. And in the next 20 years, as the pace of technological change accelerates significantly, we can expect life-expectancy to undergo a similarly accelerated increase. So its only natural that one of the worlds biggest tech giants (Google) would decide to becoming invested in the business of post-mortality.
As part of this initiative, Google has been seeking to build a computer that can think like a human brain. They even hired renowed futurist and AI expert Ray Kurzweil last year to act as the director of engineering on this project. Speaking at Google’s I/O conference late last month, he detailed his prediction that our ability to improve human health is beginning to move up an “exponential” growth curve, similar to the law of accelerating returns that governs the information technology and communications sectors today.
The capacity to sequence DNA, which is dropping rapidly in cost and ease, is the most obvious example. At one time, it took about seven years to sequence 1% of the first human genome. But now, it can be done in a matter of hours. And thanks to initiatives like the Human Genome Project and ENCODE, we have not only successfully mapped every inch of the human genome, we’ve also identified the function of every gene within.
But as Kurzweil said in the course of his presentation – entitled “Biologically Inspired Models of Intelligence” – simply reading DNA is only the beginning:
Our ability to reprogram this outdated software is growing exponentially. Somewhere between that 10- and 20-year mark, we’ll see see significant differences in life expectancy–not just infant life expectancy, but your remaining life expectancy. The models that are used by life insurance companies sort of continue the linear progress we’ve made before health and medicine was an information technology… This is going to go into high gear.
Kurzweil cited several examples of our increasing ability to “reprogram this outdated data” – technologies like RNA interference that can turn genes on and off, or doctors’ ability to now add a missing gene to patients with a terminal disease called pulmonary hypertension. He cited the case of a girl whose life was threatened by a damaged wind pipe, who had a new pipe designed and 3-D printed for her using her own stem cells.
In other countries, he notes, heart attack survivors who have lasting heart damage can now get a rejuvenated heart from reprogrammed stem cells. And while this procedure awaits approval from the FDA in the US, it has already been demonstrated to be both safe and effective. Beyond tweaking human biology through DNA/RNA reprogramming, there are also countless initiatives aimed at creating biomonitoring patches that will improve the functionality and longevity of human organs.
And in addition to building computer brains, Google itself is also in the business of extending human life. This project, called Calico, hopes to slow the process of natural aging, a related though different goal than extending life expectancy with treatment for disease. Though of course, the term “immortality” is perhaps a bit of misnomer, hence why it is amended with the word “clinical”. While the natural effects of aging are something that can be addressed, there will still be countless ways to die.
As Kurzweil himself put it:
Life expectancy is a statistical phenomenon. You could still be hit by the proverbial bus tomorrow. Of course, we’re working on that here at Google also, with self-driving cars.
Good one, Kurzweil! Of course, there are plenty of skeptics who question the validity of these assertions, and challenge the notion of clinical immortality on ethical grounds. After all, our planet currently plays host to some 7 billion people, and another 2 to 3 billion are expected to be added before we reach the halfway mark of this century. And with cures for diseases like HIV and cancer already showing promise, we may already be looking at a severe drop in mortality in the coming decades.
Combined with an extension in life-expectancy, who knows how this will effect life and society as we know it? But one thing is for certain: the study of life has become tantamount to a study of information. And much like computational technology, this information can be manipulated, resulting in greater performance and returns. So at this point, regardless of whether or not it should be done, it’s an almost foregone conclusion that it will be done.
After all? While very few people would dare to live forever, there is virtually no one who wouldn’t want to live a little longer. And in the meantime, if you’ve got the time and feel like some “light veiwing”, be sure to check out Kurzweil’s full Google I/O 2014 speech in which he addresses the topics of computing, artificial intelligence, biology and clinical immortality:
We’ve all heard about it, read about it, and seen it in the movies. Suspended Animation. The ability to put someone in a tank and chill them to the point where their heart rate, breathing, and metabolism are reduced to an absolute minimum, preserving their life or prolonging it artificially. It’s a common science fiction concept, but could such a technique ever be made feasible? That is what a team of researchers from UPMC Presbyterian Hospital in Pittsburgh, with FDA approval, are attempting to answer.
The purpose of this research is to see if suspended animation can deliver on its main promise – namely, keeping a patient alive long enough to receive life-saving treatment or surgery. Oftentimes with disease and traumatic injuries, the difference between life and death is a simple matter of timing. And for those patients who simply cannot be helped with the current level of technology and pharmacology, it is also a race against time, trying to stay alive long enough to see science catch up with the illness.
This Emergency Preservation and Resuscitation (EPR) technique isn’t quite as extreme as what we’ve come to know from science fiction franchises. Instead of reducing a patient’s temperature to near-freezing levels, it involves reducing body temperature to 10 degrees Celsius (50 degrees Fahrenheit) by inserting a cannula into the aorta and flushing cold saline into the system. This will slow the blood flow, which will prevent the body from bleeding out and slow other biological processes as well.
So far, the result have been pretty subdued – with the EPR state of induced hypothermia only being sustainable for about two hours. While this isn’t as dramatic as some may have expected, that could easily provide enough time for surgeons to perform emergency lifesaving surgery. Trauma patients who suffer cardiac arrest have a 7% chance of survival, and administering this technique could have some very real and amazing implications.
This technique was first tested by Peter Rhee in 2000 using 40 pigs, the results of which were published in 2006. After inflicting a lethal wound to simulate real-world trauma scenarios, the pigs were cooled down so the surgeons could operate then resuscitate them. While all of the control pigs died, the surgeons were able to save 90% of the pigs who had undergone suspension. None of the surviving pigs were reported to have sustained cognitive or physical impairment either.
And as per usual, animal testing is followed by human trials to see if success can be replicated. Due to the extremely time-sensitive and dire nature of the injuries of the test subjects, the FDA has declared that the surgeons will not require informed consent. As a precaution, the team took out advertisements to inform the public of the upcoming study, and even set up a website that would allow people to opt out, if desired. As of yet, nobody has opted out.
The plan for testing this process is for the team to the technique on 10 trauma patients whose injuries would be otherwise fatal. That group will be compared against 10 other patients who are not able to undergo EPR, due to the surgical team not being available. After the first increments of 10 EPR and 10 control patients, the technique will be analyzed and refined until enough data points have been collected which will allow them to analyze the efficacy of suspending life in this manner.
Should things work out, we can expect to see EPR becoming a regular part of modern medicine. And with further refinements, it may even be possible to place people in suspended animation for longer (or even indefinite) periods of time. If not, then I guess it will be just become one more of those many, many sci-fi fantasies that (like a patients in a story) will be put away until such time as the technology catches up to the fantasy.
Not long ago, designer Ernst Mauch unveiled a revolutionary new handgun that grew out of a desire to merge digital technology with firearm safety. Known as the “smart gun” – or Armatix iP1 – this pistol comes with a safety feature designed to ensure that only the guns owner may fire it. Basically, the gun comes with a watch (the iW1) that it is synchronized to, and the weapon will only fire if it is within ten inches of it. So unless you’re wearing the iW1, the weapon will not fire in your hands.
The weapon is in part the result of attempts to find intelligent solutions to gun safety and gun violence. And Mauch’s design is one of several proposed innovations to use digital/smart technology for just such a purpose. Back in January, the Smart Tech Challenges Foundation launched the first of four $1 million challenges aimed at inspiring the kinds of innovation that could help lead to safer guns – and a reduction in the number of tragic deaths and injuries that make the headlines nearly every day.
Given the recent failures to reach a legislative solution to the ongoing problem of gun-violence, these efforts should come as no surprise. And Mauch, the lead designer of the iP1, claimed in a recent op-ed piece with the Washington Post that the number of gun enthusiasts will rise as the result of its enhanced safety. As a designer who’s patents include the USP family of pistols, the HK416 assault rifle, G36 assault rifle and XM25 grenade machine gun – he is a strong advocate of a market-based solution.
The gun has already sparked a great deal of controversy amongst gun advocates and the National Rifle Association. Apparently, they worry that legislation will be passed so that only smart guns can be sold in gun stores. This is largely in response to a 2002 New Jersey law that stipulated that once the technology was available, that smart guns be sold exclusively in the state. As a result, the NRA has been quite vocal about its opposition to smart guns, despite offers made to repeal the law in exchange for them easing their position.
As already noted, the iP1 is not the only smart technology being applied to firearms. Sentini, a Detroit-based startup founded by Omer Kiyani, is designing a biometric gun lock called Identilock. Attaching to a gun’s trigger, it unlocks only when the owner applies a fingerprint. As an engineer, a gun owner, a father, and the victim of gun violence (he was shot in the mouth at 16), he too is committed to using digital technology and biometrics to make firearms safer.
An engineer by training, Kiyani spent years working as a software developer building next-generation airbag systems. He worked on calibrating the systems to minimize the chance of injury in the event of an accident, and eventually, he realized he could apply the same basic concepts to guns. As he put it:
The idea of an airbag is so simple. You inflate it and can save a life. I made the connection. I have something in my house that’s very dangerous. There’s got to be a simple way to protect it.
Initially, Kiyani considered technology that would require installing electronic locking equipment into the guns themselves, similar to what the iP1 employs. But as an engineer, he understood the inherent complications of designing electronics that could withstand tremendous shock and high temperatures, not to mention the fact it would be incredibly difficult to convince gun manufacturers to work with him on the project.
As a result, he began to work on something that anyone could add to a gun. Ultimately, his creation is different in three ways: it’s optional, it’s detachable, and it’s quick. Unlike biometric gun safes and other locking mechanisms, the Identilock makes it as easy to access a firearm as it is to unlock an iPhone. He pitched hundreds of gun owners a variety of ideas over the course of his research, but it was the biometric lock they inevitably latched onto
The Identilock is also designed using entirely off-the-shelf components that have been proven effective in other industries. The biometric sensor, for example, has been used in other security applications and is approved by the FBI. Cobbling the sensor together from existing technologies was both a cost-saving endeavor and a strategic way to prove the product’s effectiveness more quickly. Currently, the project is still in the prototype phase, but it may prove to be the breakout product that brings biometrics and safety together in recent years.
And last, but certainly not least, there is the biometric option that comes from PositiveID, the makers of the only FDA-approved implantable biochip – which is known as the Verichip. In the past, the company has marketed similar identity-confirming microchips for security and medical purposes. But this past April, the company announced a partnership with Belgium-based gun maker FN Manufacturing to produce smart weapons.
The technology is being marketed to law enforcement agencies as a means of ensuring that police firearms can never be used by criminals or third parties. The tiny chip would be implanted in a police officer’s hand and would match up with a scanning device inside a handgun. If the officer and gun match, a digital signal unlocks the trigger so it can be fired. Verichip president Keith Bolton said the technology could also improve safety for the military and individual gun owners, and it could be available as early as next year.
Similar developments are under way at other gun manufacturers and research firms. The New Jersey Institute of Technology and Australian gun maker Metal Storm Ltd. are working on a prototype smart gun that would recognize its owner’s individual grip. Donald Sebastian, NJIT vice president for research and development and director of the project, claims that the technology could eventually have an even bigger impact on the illegal gun trade.eri
Regardless of the solutions being proposed and the progress being made, opposition to these and other measures does not appear to be letting up easily. New Jersey Senate Majority Leader Loretta Weinberg recently announced that she would introduce a bill to reverse the 2002 New Jersey “smart gun” law if the National Rifle Association would agree not to stand in the way of smart gun technology. The NRA, however, has not relented in its stance.
In addition, biochips and RFID implants have a way of making people nervous. Whenever and wherever they are proposed, accusations of “branding” and “Big Brother” monitoring quickly follow. And above all, any and all attempts to introduce gun safety are met with cries of opposition by those who claim it infringes on citizen’s 2nd Amendment rights. But given the ongoing problem of gun violence, school shootings, and the amount of violence perpetrated with stolen weapon, it is clear that something needs to change.
In 2011 in the United States, roughly 3.6 people per 100,000 were killed with a firearm – which amounts to 32,163 people. In addition, of the 15,953 homicides committed that year, 11,101 were committed using a gun; almost 70% of the total. And not surprisingly, of those 11,101 gun-related homicides, more than half (An6,371) were committed using a handgun. And though exact figures are not exactly available, a general estimates indicates that some 90% percent of murders are committed with stolen guns.
As a result, it is likely just a matter of time before citizens see the value in biometric and smart gun technology. Anything that can ensure that only an owner can use a firearm will go a long way to curbing crime, accidents, and acts of senseless and unmitigated violence.
The Consumer Electronics Show has been in full swing for two days now, and already the top spots for most impressive technology of the year has been selected. Granted, opinion is divided, and there are many top contenders, but between displays, gaming, smartphones, and personal devices, there’s been no shortage of technologies to choose from.
And having sifted through some news stories from the front lines, I have decided to compile a list of what I think the most impressive gadgets, displays and devices of this year’s show were. And as usual, they range from the innovative and creative, to the cool and futuristic, with some quirky and fun things holding up the middle. And here they are, in alphabetical order:
As an astronomy enthusiast, and someone who enjoys hearing about new and innovative technologies, Celestron’s Cosmos 90GT WiFi Telescope was quite the story. Hoping to make astronomy more accessible to the masses, this new telescope is the first that can be controlled by an app over WiFi. Once paired, the system guides stargazers through the cosmos as directions flow from the app to the motorized scope base.
In terms of comuting, Lenovo chose to breathe some new life into the oft-declared dying industry of desktop PCs this year, thanks to the unveiling of their Horizon 2. Its 27-inch touchscreen can go fully horizontal, becoming both a gaming and media table. The large touch display has a novel pairing technique that lets you drop multiple smartphones directly onto the screen, as well as group, share, and edit photos from them.
Next up is the latest set of display glasses to the world by storm, courtesy of the Epson Smart Glass project. Ever since Google Glass was unveiled in 2012, other electronics and IT companies have been racing to produce a similar product, one that can make heads-up display tech, WiFi connectivity, internet browsing, and augmented reality portable and wearable.
Epson was already moving in that direction back in 2011 when they released their BT100 augmented reality glasses. And now, with their Moverio BT200, they’ve clearly stepped up their game. In addition to being 60 percent lighter than the previous generation, the system has two parts – consisting of a pair of glasses and a control unit.
The glasses feature a tiny LCD-based projection lens system and optical light guide which project digital content onto a transparent virtual display (960 x 540 resolution) and has a camera for video and stills capture, or AR marker detection. With the incorporation of third-party software, and taking advantage of the internal gyroscope and compass, a user can even create 360 degree panoramic environments.
At the other end, the handheld controller runs on Android 4.0, has a textured touchpad control surface, built-in Wi-Fi connectivity for video content streaming, and up to six hours of battery life.
The BT-200 smart glasses are currently being demonstrated at Epson’s CES booth, where visitors can experience a table-top virtual fighting game with AR characters, a medical imaging system that allows wearers to see through a person’s skin, and an AR assistance app to help perform unfamiliar tasks .
This year’s CES also featured a ridiculous amount of curved screens. Samsung seemed particularly proud of its garish, curved LCD TV’s, and even booked headliners like Mark Cuban and Michael Bay to promote them. In the latter case, this didn’t go so well. However, one curved screen device actually seemed appropriate – the LG G Flex 6-inch smartphone.
When it comes to massive curved screens, only one person can benefit from the sweet spot of the display – that focal point in the center where they feel enveloped. But in the case of the LG G Flex-6, the subtle bend in the screen allows for less light intrusion from the sides, and it distorts your own reflection just enough to obscure any distracting glare. Granted, its not exactly the flexible tech I was hoping to see, but its something!
In the world of gaming, two contributions made a rather big splash this year. These included the Playstation Now, a game streaming service just unveiled by Sony that lets gamers instantly play their games from a PS3, PS4, or PS Vita without downloading and always in the most updated version. Plus, it gives users the ability to rent titles they’re interested in, rather than buying the full copy.
Then there was the Maingear Spark, a gaming desktop designed to run Valve’s gaming-centric SteamOS (and Windows) that measures just five inches square and weighs less than a pound. This is a big boon for gamers who usually have to deal gaming desktops that are bulky, heavy, and don’t fit well on an entertainment stand next to other gaming devices, an HD box, and anything else you might have there.
Next up, there is a device that helps consumers navigate the complex world of iris identification that is becoming all the rage. It’s known as the Myris Eyelock, a simple, straightforward gadget that takes a quick video of your eyeball, has you log in to your various accounts, and then automatically signs you in, without you ever having to type in your password.
So basically, you can utilize this new biometric ID system by having your retinal scan on your person wherever you go. And then, rather than go through the process of remembering multiple (and no doubt, complicated passwords, as identity theft is becoming increasingly problematic), you can upload a marker that leaves no doubt as to your identity. And at less than $300, it’s an affordable option, too.
And what would an electronics show be without showcasing a little drone technology? And the Parrot MiniDrone was this year’s crowd pleaser: a palm-sized, camera-equipped, remotely-piloted quad-rotor. However, this model has the added feature of two six-inch wheels, which affords it the ability to zip across floors, climb walls, and even move across ceilings! A truly versatile personal drone.
Another very interesting display this year was the Scanadu Scout, the world’s first real-life tricorder. First unveiled back in May of 2013, the Scout represents the culmination of years of work by the NASA Ames Research Center to produce the world’s first, non-invasive medical scanner. And this year, they chose to showcase it at CES and let people test it out on themselves and each other.
All told, the Scanadu Scout can measure a person’s vital signs – including their heart rate, blood pressure, temperature – without ever touching them. All that’s needed is to place the scanner above your skin, wait a moment, and voila! Instant vitals. The sensor will begin a pilot program with 10,000 users this spring, the first key step toward FDA approval.
And of course, no CES would be complete without a toy robot or two. This year, it was the WowWee MiP (Mobile Inverted Pendulum) that put on a big show. Basically, it is an eight-inch bot that balances itself on dual wheels (like a Segway), is controllable by hand gestures, a Bluetooth-conncted phone, or can autonomously roll around.
Its sensitivity to commands and its ability to balance while zooming across the floor are super impressive. While on display, many were shown carrying a tray around (sometimes with another MiP on a tray). And, a real crowd pleaser, the MiP can even dance. Always got to throw in something for the retro 80’s crowd, the people who grew up with the SICO robot, Jinx, and other friendly automatons!
But perhaps most impressive of all, at least in my humble opinion, is the display of the prototype for the iOptik AR Contact Lens. While most of the focus on high-tech eyewear has been focused on wearables like Google Glass of late, other developers have been steadily working towards display devices that are small enough to worse over your pupil.
Developed by the Washington-based company Innovega with support from DARPA, the iOptik is a heads-up display built into a set of contact lenses. And this year, the first fully-functioning prototypes are being showcased at CES. Acting as a micro-display, the glasses project a picture onto the contact lens, which works as a filter to separate the real-world from the digital environment and then interlaces them into the one image.
Embedded in the contact lenses are micro-components that enable the user to focus on near-eye images. Light projected by the display (built into a set of glasses) passes through the center of the pupil and then works with the eye’s regular optics to focus the display on the retina, while light from the real-life environment reaches the retina via an outer filter.
This creates two separate images on the retina which are then superimposed to create one integrated image, or augmented reality. It also offers an alternative solution to traditional near-eye displays which create the illusion of an object in the distance so as not to hinder regular vision. At present, still requires clearance from the FDA before it becomes commercially available, which may come in late 2014 or early 2015.
Well, its certainly been an interesting year, once again, in the world of electronics, robotics, personal devices, and wearable technology. And it manages to capture the pace of change that is increasingly coming to characterize our lives. And according to the tech site Mashable, this year’s show was characterized by televisions with 4K pixel resolution, wearables, biometrics, the internet of personalized and data-driven things, and of course, 3-D printing and imaging.
And as always, there were plenty of videos showcasing tons of interesting concepts and devices that were featured this year. Here are a few that I managed to find and thought were worthy of passing on:
The year of 2013 ended with a bang for the field of health technology. And in my haste to cover as many stories as I could before the year ended, there were some rather interesting news developments which I unfortunately overlooked. But with the New Year just beginning, there is still plenty of time to look back and acknowledge these developments, which will no doubt lead to more in 2014.
The first comes from the UK, where the ongoing fight against cancer has entered a new phase. For years, researchers have been developing various breathalyzer devices to help detect cancer in its early phases. And now, a team from the University of Huddersfield plans to introduce one such cancer-detecting breathalyser (known as the RTube) into pharmacies.
According to Dr Rachel Airley, the lead researcher of the Huddersfield team, these molecules – which consist of genes, proteins, fragments of cells, secretions and chemicals produced by the metabolism of living tissue with the disease – form a kind of chemical and biological signature. Using breath testing devices like the RTube, Dr Airley developed a project to define a lung cancer “biomarker signature” that is detectable in breath.
According to Dr Airley:
When you get certain chemicals in someone’s breath, that can be a sign that there is early malignancy. We are looking to be able to distinguish between patients with early lung cancer and patients who have maybe got bronchitis, emphysema or non-malignant smoking related disease… or who have maybe just got a cough.
The goal of the project is to validate the signature in a large number of patients to ensure it can reliably distinguish between lung cancer and non-cancerous lung disease. Dr. Airley told us that this will require tracking the progress of patients for up to five years to see if the disease develops and can be linked back to a signature picked up in the patient’s breath at the beginning of the project.
So far, the project has secured £105,000 (US$170,000) in funding from the SG Court Pharmacy Group with the University of Huddersfield providing matching funding. The SG also operates the chain of pharmacies in the South East of England where the initial trials of the breathalyzer technology will be carried out.
The researchers predict that people visiting their local pharmacy for medication or advice to help them quite smoking will be invited to take a quick test, with the goal of catching the disease before the patients start to experience symptoms. Once symptoms present themselves, the disease is usually at an advanced stage and it is often too late for effective treatment.
Dr Airley stresses that the trial is to test the feasibility of the pharmacy environment for such a test and to ensure the quality of the test samples obtained in this setting are good enough to pick up the signature:
There are 12,000 community pharmacies in Britain and there is a big move for them to get involved in primary diagnostics, because people visit their pharmacies not just when they are ill but when they are well. A pharmacy is a lot less scary than a doctor’s surgery.
Dr Airley also says her team is about to start collecting breath samples from healthy volunteers and patients with known disease as a reference point and hope to start the pharmacy trials within two years. If all goes well, she says it will be at least five years before the test is widely available.
The next comes from Germany, where researchers have created a test that may help doctors predict one of the most severe side effects of antidepressants: treatment-emergent suicidal ideation (TESI). The condition is estimated to affect between four and 14 percent of patients, who typically present symptoms of TESI in the first weeks of treatment or following dosage adjustments.
So far doctors haven’t been able to find the indicators that could predict which patients are more likely to develop TESI, and finding the right medication and testing for side-effects is often a matter of simple trial and error. But a new test based on research carried out by the Max Planck Institute of Psychiatry in Munich, Germany, could change all that.
The researchers carried out genome-wide association studies on 397 patients, aged 18 to 75, who were hospitalized for depression, but were not experiencing suicidal thoughts at the time they began treatment. During the study, a reported 8.1 percent of patients developed TESI, and 59 percent of those developed it within the first two weeks of treatment.
To arrive at a list of reliable predictors, the team genotyped the whole group and then compared patients who developed TESI with those who didn’t. Ultimately, they found a subset of 79 genetic variants associated with the risk group. They then conducted an independent analysis of a larger sample group of in-patients suffering from depression and found that 90 percent of the patients were shown to have these markers.
In short, this test has found that the most dangerous side-effect of antidepressant use is genetic in nature, and can therefore be predicted ahead of time. In addition, the research shed new light on the age of those affected by TESI. Prior to discovering that all age groups in the study were at risk, the assumption had been that under-25s were more at risk, leading to the FDA to begin issuing warnings by 2005.
According to some experts, this warning has had the effect of reducing the prescription of antidepressants when treating depression. In other words, patients who needed treatment were unable to get it, out of fear that it might make things worse. This situation could now be reversed that doctors can avail themselves of this new assessment tool based on the research.
The laboratory-developed test, featuring a DNA microarray (chip), is being launched immediately by US company Sundance Diagnostics, ahead of submission to the FDA for market clearance. As Sundance CEO Kim Bechthold said in a recent interview:
A DNA microarray is a small solid support, usually a membrane or glass slide, on which sequences of DNA are fixed in an orderly arrangement. It is used for rapid surveys of the presence of many genes simultaneously, as the sequences contained on a single microarray can number in the thousands.
Ultimately, according to Bechthold, the aim here is to assist physicians in significantly reducing the risk of suicide in antidepressant use, and also to provide patients and families with valuable personal information to use with their doctors in weighing the risks and benefits of the medications.
Wow! From detecting cancer to preventing suicides, the New Year is looking bright indeed! Stay tuned for good news from the field of future medicine!
Scientists and researchers have been making great strides in the fight against HIV/AIDS in recent years. In addition to developing vaccines that have shown great promise, there have even been some treatments that have been shown to eliminate the virus altogether. And it seems that with this latest development, which was published in Nature earlier this month, there might be a treatment that can double as a cure.
Developed at the Vaccine and Gene Therapy Institute at the Oregon Health and Science University (OHSU), this new vaccine proved successful in about fifty percent of the clinical subjects that were tested, and may be able to cure patients who are currently on anti-retroviral drugs. If successful, this could mean that a preventative vaccine and cure could come in the same package, thus eliminating HIV altogether.
Currently, anti-retroviral drugs and HIV vaccine typically aim at improving the immune response of the patient in the long term. However, they are limited in that they can never completely clear the virus from the body. In fact, aside from a very few exceptional cases, researchers have long believed that HIV/AIDS could only be contained, but not completely cured.
The OHSU team, led by Dr. Louis Picker, has been working on its own vaccine for the past 10 years. In that time, their research has shown that an immune response can in fact go beyond containment and systematically wipe the virus out of the body. As with most early vaccine candidates, the study revolves around SIV – a more aggressive virus than HIV that can replicate up to 100 times faster and, unchecked, can cause AIDS in only two years.
Picker and his research team created the vaccine by working with cytomegalovirus (CMV), another virus which is itself persistent, but doesn’t cause disease. In their initial tests, the vaccine was found to generate an immunoresponse very similar to that generated by CMV, where T-cells that can search and destroy target cells were created and remained in the system, consistently targeting SIV-infected cells until the virus was cleared from the body.
For the sake of their clinical trials, simian subjects were used that were infected by the HIV virus. When treated with the team’s vaccine, half of the subjects initially showed signs of infection, but those signs gradually receded before disappearing completely. This sets it apart from other vaccines which also generate an immunoresponse, but one which fades over time.
According to Dr. Picker, it is the permanency of the T-cells that allows the immunoresponse to be consistent and slowly eradicate the virus, eventually eliminating it completely from the system. Says Dr. Picker of their trials and the possibilities for the vaccine:
The virus got in, it infected some cells, moved about in various parts of the body, but it was subsequently cleared, so that by two or three years later the monkeys looked like normal monkeys. There’s no evidence, even with the most sensitive tests, of the SIV virus still being there... We might be able to use this vaccine either to prevent infection or, potentially, even to apply it to individuals who are already infected and on anti-retroviral therapy. It may help to clear their infections so ultimately they can go off the drugs.
Currently, Picker and his the team are trying to understand why some of the vaccinated animals did not respond positively, in the hopes of further increasing the efficacy of the vaccine. Once these trials are complete, it could be just a hop, skip and a jump to getting FDA approval and making the vaccine/cure available to the open market.
Imagine, if you will, a world where HIV/AIDS is on the decline, and analysts begin predicting how long it will take before it is eradicated entirely. At this rate, such a world may be just a few years away. For those working in the field of medicine, and those of us who are around to witness it all, it’s an exciting time to be alive!
And be sure to enioy this video from OHSU where Dr. Picker speak about their vaccine and the efforts to end HIV:
The fight to end HIV has been long and ongoing. But in recent years, researchers have made some incredible breakthroughs in terms of treatment and vaccines. Well as it turns out, the fight may be getting a punch in the arm from a most unlikely source – an anti-fungal foot cream! Yes, not only does this common drug kill HIV, it is even more effective than some of today’s most cutting-edge drugs.
In a study performed at Rutgers New Jersey Medical School, the drug Ciclopirox was shown to completely eradicate infectious HIV when applied to cell cultures of the virus. But what was even more impressive was the fact that the virus didn’t bounce back when the drug was withheld. This means that, unlike most anti0viral drugs, it may not require a lifetime of use to keep HIV at bay.
The same group of researchers had previously shown that Ciclopirox – which was approved by the FDA and Europe’s EMA to treat foot fungus – inhibits the expression of HIV genes. Now they have found that it also blocks the essential function of the mitochondria, which results in the reactivation of the cell’s suicide pathway, all while sparing surrounding healthy cells.
This is key since one of the worst aspects of HIV – one that makes it particularly persistent, even in the face of strong antiviral treatments – is its ability to disable a cell’s altruistic suicide pathway. This “self-destruct protocol” is typically activated when a cell is damaged or infected. With the introduction of Ciclopirox, these cells are tricked into pulling a double negative, disabling the disabling of the suicide pathway.
Naturally, the cream will have to be tested on humans before its efficacy as a topical HIV treatment can be tested. However, the fact that it’s already been deemed safe for one type of human use could make the regulatory process faster than usual. In fact, the researchers have noted that another FDA-approved drug now thought to help subdue HIV (called Deferiprone) skipped animal studies and went straight to human trials in South Africa.
Naturally, the Rutgers team hopes they too can go directly from their culture studies to human trials, and that the case involving Deferiprone will pave the way for a more streamlined testing process. This is likely, seeing as how there have been many breakthroughs in recent months and everyone – from researchers to patients to medical authorities – want to make treatments available as soon as possible.